Please assess the completion status of the following clinical trial:

Trial Title: Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Benign Prostatic Hyperplasia, based on medical history~* Voiding symptoms~Exclusion Criteria:~* Urgent need for prostate surgery or prior surgical treatment of the prostate or bladder~* Major organ dysfunction~* Eczema (atopic dermatitis) treated during the last 6 months~* Current or recent treatment with sexual hormone drugs or 5 α reductase inhibitors or botulinum toxin type a (Botox) within the last 6 months prior randomization or with α blockers or saw palmetto within the last 6 weeks prior to randomization~* Urologic disorders including neurogenic bladder dysfunction due to diabetes mellitus or documented neurologic disorder, urethral stricture disease or history of pelvic radiation therapy~* History of acute obstructive, infectious, or neurological disorders of the genitourinary tract within the last 3 months

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group A: CET 78 mg + 78 mg (Type: EXPERIMENTAL): Treatment course 1: Cetrorelix 78 mg + 78 mg~* Week 0: 52 mg CET (2 injections)~* Week 2: 26 mg CET (1 injection)~Treatment course 2:~* Week 26: 52 mg CET (2 injections)~* Week 28: 26 mg CET(1 injection)~  4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient.
- Treatment Group B: CET 78 mg + 52 mg (Type: EXPERIMENTAL): Treatment course 1: Cetrorelix 78 mg + 52 mg~* Week 0: 52 mg CET (2 injections)~* Week 2: 26 mg CET (1 injection)~Treatment course 2:~* Week 26: 52 mg CET (2 injections)~* Week 28: Placebo (1 injection)~  4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient.
- Treatment Group C: Placebo (Type: PLACEBO_COMPARATOR): Treatment course 1:~* Week 0: placebo (2 injections)~* Week 2: placebo (1 injection)~Treatment course 2:~* Week 26: placebo (2 injections)~* Week 28: placebo (1 injection)~  4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).